膦甲酸钠氯化钠注射液在血液病合并EBV感染中的疗效和安全性分析

叶敬伟; 郭晓玲; 李焱

doi:10.13201/j.issn.1004-2806.2018.01.010

膦甲酸钠氯化钠注射液在血液病合并EBV感染中的疗效和安全性分析

- 1. 邯郸市第一医院血液内科(河北邯郸, 056002);
- 2. 河北医科大学第二医院血液内科

详细信息

通讯作者: 李焱,E-mail:handanliyan68@sohu.com

中图分类号: R733

收稿日期: 2017-08-24

Efficacy and safety of foscarnet sodium in the treatment of EBV infection in hematopathy patients

- 1. Department of Hematology, the First Hospital of Handan City, Handan, 056002, China;
- 2. Department of Hematology, the Second Hospital of Hebei Medical University

More Information

Corresponding author: LI Yan, E-mail: handanliyan68@sohu.com

Received Date: 24 August 2017

摘要

摘要: 目的:探讨膦甲酸钠氯化钠注射液治疗血液病合并EBV感染的疗效和安全性。方法:回顾分析86例应用膦甲酸钠氯化钠注射液治疗的血液病合并EBV感染的患者情况,记录患者治疗前后EBV-DNA拷贝数变化,观察临床症状变化。疗效评价参数:转阴率、显效率、总体有效率、无效率,以及不良事件发生率等。结果:86例患者治疗前后EBV-DNA拷贝数比较差异有统计学意义(P=0.039)。其中EBV-DNA拷贝数转阴52例,转阴率60.47%;显效6例,显效率6.98%;总体有效率67.44%(58/86);无效28例,无效率32.56%。不良反应发生率30.23%(26/86),无严重不良反应。结论:膦甲酸钠可以明显降低血液病患者EBV感染的病毒载量,对发热、肝脾肿大等有明显治疗作用,无严重不良反应,可以安全应用于临床。
- EB病毒 /
- 血液病 /
- 膦甲酸钠 /
- 治疗
Abstract: Objective:To investigate the clinical effect and safety of foscarnet sodium in treatment of hematopathy patients combined with EBV-infection.Method:We retrospectively analyzed 86 inpatients of hematopathy combined with EBV-infection treated with foscarnet sodium.We recorded the changes of EBV-DNA copy number before and after treatment,and observed the treatment effect.Evaluation parameters included the negative rate,significant efficiency,overall efficiency,inefficiency,and the incidence of adverse events.Result:Among 86 cases,there was significant difference in EBV-DNA copy numbers before and after treatment (P=0.039).There were 52 patients with EBV-DNA copy number of negative,the negative rate was 60.47%,6 patients had a significant effect and the significant efficiency was 6.98%,the total effective rate was 67.44%(58/86),invalid number of cases was 28 and invalid rate was 32.56%.The incidence of adverse reactions was 30.23%(26/86),no serious adverse reactions were observed.Conclusion:Foscarnet sodium and sodium chloride injection can significantly reduce viral load in hematopathy patients combined with EBV-infection,it has significant therapeutic effects on fever,liver and spleen enlargement,with no serious adverse reactions.It can be safely used in clinic.
- EBV /
- hematopathy /
- foscarnet /
- treatment

HTML全文

参考文献(6)

[1]	Cohen JI.Epstein-Barr virus infection[J].N Engl J Med, 2012, 343:481-492.
[2]	Fafi-Kremer S, Morand P, Brion JP, et al.Long-term shedding of infectious epstein-barr virus after infectious mononucleosis[J].J Infect Dis, 2015, 191:985-989.
[3]	Karoline B, Jindrich C, Jonas SC.Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet[J].Med Microbiol Immunol, 2011, 200:193-202.
[4]	Safrin S, Crumpacker C, Chatis P, et al.A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplexin the acquired immunodeficiency syndrome[J].N Engl J Med, 2013, 325:551-555.
[5]	Wagstaff AJ, Bryson HM.Foscarnet.A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocom promised patients with viral infections[J].Drugs, 1994, 48:199-226.
[6]	Mao JC, Robishaw EE, Overby LR.Inhibition of DNA polymerase from herpes simplex virus infected wi-38cells by phosphonoacetic acid[J].J Virol, 2014, 15:1281-1283.